Investment Thesis
Emergent BioSolutions exhibits severe financial distress with an interest coverage ratio of 0.4x, indicating the company cannot service its $589.7M debt from operating income. Compounding this crisis, the company generated negative operating cash flow of -$33.8M and free cash flow of -$36.2M, demonstrating unsustainable cash burn. Combined with zero revenue growth and extremely poor returns (ROE 1.3%, ROA 0.5%), the company faces imminent refinancing or restructuring risks.
Strengths
- Strong liquidity position with current ratio of 4.29x and $160.3M cash reserves providing short-term operational runway
- Net income improved 127.6% year-over-year, showing recent operational progress from depressed base
- Gross profit of $261M exceeds revenue, suggesting potential for margin recovery if operational efficiency improves
Risks
- Critical: Interest coverage ratio of 0.4x means operating income cannot cover debt service obligations—indicates high default risk
- Persistent negative operating cash flow (-$33.8M) and negative free cash flow (-$36.2M) are unsustainable; company is burning cash despite positive net income
- Complete revenue stagnation (0% YoY growth) with microscopic margins (4.4% net) leaves no buffer for debt obligations or adverse events
- Debt-to-equity ratio of 1.13x combined with operational losses suggests potential covenant violations or forced restructuring
- Abnormally elevated gross margin (167.2%) raises data quality concerns and masks true operational performance
Key Metrics to Watch
- Interest coverage ratio—must exceed 1.5x to reduce default risk
- Operating cash flow—must turn positive to validate business sustainability
- Revenue growth trajectory—stagnation at 0% YoY is unacceptable for debt service
- Debt refinancing activity and covenant compliance
- Cash burn rate and runway remaining before liquidity crisis
Financial Metrics
Revenue
156.1M
Net Income
6.8M
EPS (Diluted)
$0.07
Free Cash Flow
-36.2M
Total Assets
1.3B
Cash
160.3M
Profitability Ratios
Gross Margin
167.2%
Operating Margin
6.7%
Net Margin
4.4%
ROE
1.3%
ROA
0.5%
FCF Margin
-23.2%
Balance Sheet & Liquidity
Current Ratio
4.29x
Quick Ratio
2.08x
Debt/Equity
1.13x
Debt/Assets
60.4%
Interest Coverage
0.43x
Long-term Debt
589.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:29:55.038178 |
Data as of: 2026-03-31 |
Powered by Claude AI